AbbVie
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
CEORobert A. Michael
CEORobert A. Michael
Employees55,000
Employees55,000
HeadquartersNorth Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded2011
Founded2011
Employees55,000
Employees55,000
ABBV Key Statistics
Market cap333.96B
Market cap333.96B
Price-Earnings ratio81.34
Price-Earnings ratio81.34
Dividend yield3.34%
Dividend yield3.34%
Average volume8.16M
Average volume8.16M
High today$191.39
High today$191.39
Low today$188.29
Low today$188.29
Open price$191.39
Open price$191.39
Volume3.71M
Volume3.71M
52 Week high$218.66
52 Week high$218.66
52 Week low$163.63
52 Week low$163.63
ABBV News
TipRanks 15h
AbbVie’s XEN63 Gel Stent Study: A New Hope for Glaucoma Treatment?Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...
TipRanks 15h
AbbVie’s Pediatric Crohn’s Disease Study: A Potential Game-Changer?Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...
TipRanks 3d
AbbVie Stock Jumps on $2.1B Capstan Therapeutics DealAbbVie (ABBV) stock rallied on Monday after the company announced its $2.1 billion agreement to acquire Capstan Therapeutics. It will use cash to fund this tran...
Analyst ratings
60%
of 30 ratingsBuy
60%
Hold
40%
Sell
0%
More ABBV News
Seeking Alpha 4d
AbbVie to acquire Capstan Therapeutics for up to $2.1B in cashAbbVie (NYSE:ABBV) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash. The transaction is subject t...
People also own
Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.